Nektar Therapeutics (NKTR) — Capital Reinvestment Ratio
Latest as of June 2018:
0.00x
Nektar Therapeutics (NKTR) has a Capital Reinvestment Ratio of 0.00x as of June 2018, meaning it reinvests 0% of its operating cash flow ($959.64 Million) in capital expenditures ($2.75 Million). See NKTR FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$959.64 Million
USD
Capital Expenditures
$2.75 Million
USD
Data as of
Jun 2018
Most recent filing
Nektar Therapeutics Capital Reinvestment Ratio (1997–2018)
This chart tracks Nektar Therapeutics's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Nektar Therapeutics (1997–2018)
Year-by-year Capital Reinvestment Ratio for Nektar Therapeutics from 1997 to 2018. For live market cap and broader valuation context, see Nektar Therapeutics market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 0.02x | $718.21 Million | $14.24 Million | ▼ -96.2% |
| 2009 | 0.52x | $39.74 Million | $20.70 Million | ▲ +132.4% |
| 2007 | 0.22x | $146.30 Million | $32.80 Million | ▼ -93.5% |
| 1997 | 3.47x | $4.98 Million | $17.26 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow